Olivia Spleiss

TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.

TL;DR: Vemurafenib inhibits tumor proliferation and oncogenic BRAF signaling through the MAPK pathway and inhibition downstream of BRAF should help to overcome acquired resistance.

TL;DR: In this article, the authors used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients.

TL;DR: Variation in genes of immune response and pharmacodynamic/pharmacokinetic relevance may be important in understanding acute rejection after renal transplant.

TL;DR: A selection of case studies from the first 5 years of the US Food and Drug Administration's voluntary exploratory data submission programme, which also involves collaboration with the European Medicines Agency, are discussed, and general lessons are highlighted.